Photovoltaic co 3GSolar raises $2.5m from HuaXiang

3GSolar's low-cost DSC modules provide an alternative to traditional PV modules, such as thin film and crystalline silicon.

Chinese industrial and real estate giant HuaXiang Group has made a $2.5 million investment in Jerusalem-based start up 3GSolar Photovoltaics Ltd. HuaXiang reported that this is the company's first investment in Israel.

Based on highly-efficient, low-cost DSC modules, with a focus on the global photovoltaic (PV) market, 3GSolar provides an alternative to traditional PV modules, such as Thin Film and Crystalline Silicon. 3GSolar’s DSC cells are a 3rd generation technology of solar PV cells for solar power generation, stemming from a photosynthesis-like process that uses a sandwich of dye coated titanium oxide and a counter electrode to create an electrical current on illumination.

Joma International, a leader in highly engineered titania materials is a strategic partner of 3GSolar, and professors from Bar Ilan University and the Weizmann Institute of Science are academic partners.

3GSolar's investors include Israel Electric Corporation (IEC) (TASE: ELEC.B22) and London-based Smedvig Capital, part of the Smedvig Group.

Published by Globes [online], Israel business news - www.globes-online.com - on December 17, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters גלובס